Industry engagement opportunities

Several companies have established initiatives to support collaborative engagement between academic researchers and industry research teams.

For some of those listed below, the University of Melbourne has been selected to participate in the relevant programs.

Should you be interested in discussing any of these opportunities, please contact the designated MDHS Business Development team member.

Pfizer Centers for Therapeutic Innovation (CTI) program

  • Unique joint drug discovery model focused on academic/Pfizer collaboration that include funding, access to Pfizer expertise and infrastructure, potential for in-licensing and involvement in CTI’s Foundation Alliances
  • Pfizer is particularly seeking opportunities related to:
    • Tissue-resident immunity in inflammation, fibrosis, autoimmunity and oncology,
    • DNA damage response and replicative stress in immunology, oncology and rare diseases, and
    • Targeting the cause of repeat expansion disorders.

For further information please contact Dhiraj Hans

Bayer Collaborative Partnerships

  • Bayer are seeking disruptive technologies in its key areas of interest:
    • cardiovascular, oncology, gynaecology and ophthalmology
    • novel biologics, cell lines, biomarkers, biospecimen, disease genomics and formulations.

For further information please contact Jerome Wielens

CSL Research Acceleration Initiative 

  • Fast-track translation of innovative biotherapies in partnership with CSL
  • Eligible projects must be focused on:
    • novel drug targets, therapeutic candidates or novel disease treatment strategies
    • in one of CSL’s therapeutic areas of interest (immunology, neurology, haematology, thrombosis, transplant, respiratory, cardiovascular/metabolic).
    • that are amenable to antibody, protein therapeutics, gene therapy and cell therapy treatment modalities.
  • Up to $500,000 is available for collaborative research projects with CSL.

For further information please contact Jerome Wielens

Novartis Institutes for Biomedical Research (NIBR) Global Scholars Program 

  • The University of Melbourne is one of a select group of institutions globally that has been invited to participate in the NIBR program
  • This program is focused on novel science that can be translated to drug discovery and/or clinical research
  • Successful applicants receive up to USD 1 million for a collaborative research project with Novartis over three years

For further information please contact Jerome Wielens

2021 CSL Centenary Fellowships

  • The CSL Centenary Fellowships are high-value, long-term, competitively-selected grants available to outstanding Australian researchers seeking to consolidate their career and undertake medical research in an Australian academic institution.  Two five-year fellowships are to be awarded each calendar year, for ten years.  The total value of each award is A$1.25 million.
  • Applications are open for the two 2021 fellowships to commence on 1 January 2021.  Applications will be accepted from 1st June - 31st July 2020.
  • For further details please contact Jerome Wielens